Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A pivotal trial of ARCT-810 in OTC Deficiency

Next Previous
Trial Profile

A pivotal trial of ARCT-810 in OTC Deficiency

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 16 Mar 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ARCT 810 (Primary)
  • Indications Ornithine carbamoyltransferase deficiency disease
  • Focus Therapeutic Use

Most Recent Events

  • 03 Mar 2026 According to a Arcturus Therapeutics media release, The scheduled Type C regulatory meetings with health authorities, along with the associated feedback, remain on track for the first half of 2026.
  • 09 Dec 2025 New trial record
  • 10 Nov 2025 According to a Arcturus Therapeutics media release, company continues to advance the ARCT-810 program for OTC deficiency. Planned alignment with regulatory agencies around pivotal trial strategy for both pediatric and adult populations remain on track for the first half of 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top